Worth reading
53Recurring
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-7.2
% (year-on-year change in consolidated net sales)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2022年7月1日〜2023年3月31日ConsolidatedJapanese GAAPNet Sales6,586,192¥ thousandYear on year -7.2%
Operating profit784,613¥ thousandYear on year -15.7%
Ordinary income785,486¥ thousandYear on year -19.5%
Net income attributable to owners of the parent496,221¥ thousandYear on year -22.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets8,679,982¥ thousand
of which net assets 7,216,796 ¥ thousand
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueBiological Assessment Systems ¥404,455 thousand (YoY +20.3%), Healthcare Support ¥463,329 thousand (YoY +2.3%), Cosmetics ¥3,412,783 thousand (YoY -7.8%), Health Supplements ¥1,924,584 thousand (YoY -9.8%), Functional Materials Development ¥379,839 thousand (YoY -18.7%)
Segment profitBiological Assessment Systems ¥67,768 thousand, Healthcare Support ¥83,134 thousand (YoY -6.5%), Cosmetics ¥700,921 thousand (YoY -21.5%), Health Supplements ¥115,354 thousand (YoY -7.2%), Functional Materials Development ¥43,209 thousand (YoY -42.7%)
Factors Behind Changes in Business Performance
生体評価システムは売上増により営業損益が損失から利益に転じた。ヘルスケアサポートは売上が増加した一方、営業利益は減少。化粧品は中国市場での競争激化等により減収減益。健康補助食品は広告宣伝費の未消化、広告料高騰による広告効率悪化、新規顧客獲得数の減少等により減収減益。機能性素材開発はラクトフェリン原料の販売数量の伸び悩みにより減収減益。
Disclosure regarding the going concern assumption
Not applicable.
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥1,887 thousand
Orders received and order backlog生体評価システム・評価試験 Orders received ¥153 million / Order backlog ¥130 million / 生体評価システム・医薬臨床研究支援 Orders received ¥158 million / Order backlog ¥144 million / Healthcare Support Orders received ¥463 million / Order backlog No
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2022年7月1日〜2023年3月31日 |
| Net Sales | ¥6,586,192 thousand (YoY -7.2%) |
| Operating profit | ¥784,613 thousand (YoY -15.7%) |
| Ordinary income | ¥785,486 thousand (YoY -19.5%) |
| Profit attributable to owners of the parent | ¥496,221 thousand (YoY -22.5%) |
| Total assets | ¥8,679,982 thousand |
| Net assets | ¥7,216,796 thousand |
| Segment revenue | Biological Assessment Systems ¥404,455 thousand (YoY +20.3%), Healthcare Support ¥463,329 thousand (YoY +2.3%), Cosmetics ¥3,412,783 thousand (YoY -7.8%), Health Supplements ¥1,924,584 thousand (YoY -9.8%), Functional Materials Development ¥379,839 thousand (YoY -18.7%) |
| Segment profit | Biological Assessment Systems ¥67,768 thousand, Healthcare Support ¥83,134 thousand (YoY -6.5%), Cosmetics ¥700,921 thousand (YoY -21.5%), Health Supplements ¥115,354 thousand (YoY -7.2%), Functional Materials Development ¥43,209 thousand (YoY -42.7%) |
| Orders received and order backlog | 生体評価システム・評価試験 Orders received ¥153 million / Order backlog ¥130 million / 生体評価システム・医薬臨床研究支援 Orders received ¥158 million / Order backlog ¥144 million / Healthcare Support Orders received ¥463 million / Order backlog No |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥1,887 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Factors Behind Changes in Business Performance | 生体評価システムは売上増により営業損益が損失から利益に転じた。ヘルスケアサポートは売上が増加した一方、営業利益は減少。化粧品は中国市場での競争激化等により減収減益。健康補助食品は広告宣伝費の未消化、広告料高騰による広告効率悪化、新規顧客獲得数の減少等により減収減益。機能性素材開発はラクトフェリン原料の販売数量の伸び悩みにより減収減益。 |
Items this document does not state (21)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesDepreciation and amortizationChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品は中国市場で現地国内メーカーの台頭による競争激化等、健康補助食品は広告宣伝費の未消化や広告料高騰による広告効率悪化、新規顧客獲得数の減少、機能性素材開発はラクトフェリン原料の販売数量の伸び悩みが理由として挙げられている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.